Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing. Wall Street analysts project Vertex will increase earnings by nearly 70% annually over the next few years. If the biotech comes anywhere close to that level of growth, Vertex's market cap will move even higher.
Interestingly, Vertex COO Ian Smith said at the Leerink conference in New York on Wednesday that his company often compares itself to Gilead Sciences (NASDAQ: GILD). According to Smith, Vertex's goal is to do in cystic fibrosis (CF) what Gilead has done in HIV. Can Vertex pull it off?
Image source: Getty Images.
Source: Fool.com
Vertex Pharmaceuticals Inc. Stock
€433.75
-0.090%
The stock is one of the favorites of our community with 60 Buy predictions and 2 Sell predictions.
With a target price of 459 € there is a slightly positive potential of 5.82% for Vertex Pharmaceuticals Inc. compared to the current price of 433.75 €.
